Two new genes involved in the more aggressive prostate cancer

This is researcher Alvaro Aytes. Credit: Toni Soriano (ICO)

A study by the Columbia University Nova York, in collaboration with the Catalan Institute of Oncology , Belvitge Biomedical Research Institute (ICO-IDIBELL) has identified two new genes that lead to more aggressive forms of prostate cancer. The work done by Alvaro Aytes under the direction of Cory Abate-Shen , director of the Herbert Irving Comprehensive Cancer Center of the Columbia University, has been published in the latest issue of Cancer Cell.

Prostate cancer

Prostate cancer is the most common in men in Europe( accounts for 20% of all male tumors). The incidence is about 60 new cases per 100,000 inhabitants per year.

A tumor closely associated with old age, and most cases is diagnosed between 70 and 80 years. The progressive aging of the population has made it one of the tumors that has increased in recent decades. Survival is quite high: according to Oncology Master Plan, 84 % of patients are alive five years after diagnosis.

Identify high-risk patients

In a significant proportion of patients the has a not very aggressive behavior, which does not compromise the health and quality of life of the affected. Also, being a tumor that usually occurs in old age, often the person dies with the tumor but not as a result of this.

It is therefore necessary to develop tools to predict which prostate tumors are clinically relevant and potentially lethal. This would open the door to customize treatments and avoid certain therapies and , therefore, avoid side effects to patients that do not need it, further reducing healthcare costs.

Two new genes in the spotlight

The study published in Cancer Cell identified two genes, the FOXM1 and CENPF, if they are abnormally activated simultaneously, lead to more aggressive and life threatening forms of prostate cancer .

A new feature of the study is that computer algorithms were used to generate networks of interactions between molecules that are generated specifically in .

Currently they have launched preclinical studies to determine which treatments or combinations of drugs are more effective in combating abnormal activation of FOXM1 and CENPF genes. Also, in the near future, identifying the presence or absence of these biomarkers in an individual patient will provide a more effective and with fewer side effects individualized treatment.

add to favorites email to friend print save as pdf

Related Stories

Two genes together drive aggressive prostate cancer

May 12, 2014

Two genes work together to drive the most lethal forms of prostate cancer, according to new research from the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). These findings could lead ...

Vitamin D deficiency linked to aggressive prostate cancer

May 01, 2014

African-American and European-American men at high risk of prostate cancer have greater odds of being diagnosed with an aggressive form of the disease if they have a vitamin D deficiency, according to a new study from Northwestern ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.